Ligand Pharmaceuticals Incorporated announced it has entered a worldwide OmniAb platform license agreement with Glenmark Pharmaceuticals. Under the license, Glenmark will be able to use the full OmniAb platform including OmniChicken™, OmniRat®, OmniMouse® and OmniFlic® to discover fully human mono- and multispecific antibodies. Ligand is eligible to receive annual platform access payments, development and regulatory milestone payments and tiered royalties for each product incorporating an OmniAb antibody. Glenmark will be responsible for all costs related to the programs.